Nonetheless, there are still many patients who cannot benefit from immunotherapy because many factors, such as programmed cell death protein 1 ligand 1 (PD-L1) expression and tumor mutation burden, limit the response of many patients to immunotherapy (224). The gene discussed is CD274; the disease is neoplasm.